Back to Search
Start Over
Effect of the PCV 10 vaccination on community-acquired pneumonia hospitalisations after four years of its introduction into the Polish National Immunisation Programme: Follow-up study.
- Source :
-
Vaccine [Vaccine] 2024 May 10; Vol. 42 (13), pp. 3257-3262. Date of Electronic Publication: 2024 Apr 18. - Publication Year :
- 2024
-
Abstract
- Background: Vaccination against pneumococci is currently the most effective method of protection against pneumococcal infections. The aim of the study was to analyse changes in hospitalisations and in-hospital deaths due to pneumonia before (2009-2016) and after (2017-2020) the introduction of PCV 10 vaccinations in the National Immunisation Programme in Poland.<br />Methods: Data on hospitalisations related to community acquired pneumonia (CAP) in the years 2009-2020 were obtained from the Nationwide General Hospital Morbidity Study. Analyses were made in the age groups: <2, 2-3, 4-5, 6-19, 20-59, 60+ years in 2009-2016 and 2017-2020.<br />Results: Overall, there were 1,503,105 CAP-related hospitalisations in 2009-2020, 0.7% of which were caused by Streptococcus pneumoniae infections. Children <2 years of age were the most frequently hospitalised for CAP per 100,000 population, followed by patients aged 2-3, 4-5 and 60+ years. In the years 2009-2016, the percentage of CAP hospital admissions increased significantly, and after the year 2017, it decreased significantly in each of the age groups (p<0.001). In the years 2009-2016, a significant increase in hospitalisations for Streptococcus pneumoniae infections was observed in the age groups <2, 2-3 and 4-5 years (p<0.05). A significant reduction in hospitalisations was observed in the age groups <2, 20-59 and 60+ in 2017-2020 (p<0.05). In the years 2009-2020, there were 84,367 in-hospital deaths due to CAP, 423 (0.5%) of which due to Streptococcus pneumoniae, with patients mainly aged 60+.<br />Conclusions: Implementation of the PCV vaccination programme has effectively decreased the incidence of CAP hospitalisations, including children <2 years of age. The group that is most at risk of death are persons aged 60+. The results of our study can be useful in evaluating the vaccine efficacy and benefits, and they can be an essential part of public health policy. Effective prevention strategies for CAP should be implemented in different age groups.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 The Author(s). Published by Elsevier India Pvt Ltd. All rights reserved.)
- Subjects :
- Humans
Child, Preschool
Poland epidemiology
Middle Aged
Adult
Male
Female
Infant
Young Adult
Child
Adolescent
Aged
Follow-Up Studies
Streptococcus pneumoniae immunology
Aged, 80 and over
Pneumococcal Infections prevention & control
Pneumococcal Infections epidemiology
Pneumococcal Infections mortality
Pneumococcal Vaccines administration & dosage
Pneumococcal Vaccines immunology
Community-Acquired Infections prevention & control
Community-Acquired Infections epidemiology
Community-Acquired Infections mortality
Hospitalization statistics & numerical data
Immunization Programs
Pneumonia, Pneumococcal prevention & control
Pneumonia, Pneumococcal epidemiology
Pneumonia, Pneumococcal mortality
Vaccination statistics & numerical data
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2518
- Volume :
- 42
- Issue :
- 13
- Database :
- MEDLINE
- Journal :
- Vaccine
- Publication Type :
- Academic Journal
- Accession number :
- 38641493
- Full Text :
- https://doi.org/10.1016/j.vaccine.2024.04.019